Skip to main content

Table 1 Screening results

From: Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis

Age participant [years, median (IQR)]

22 (20–25)

Self-identified race [% (n/N)]

 Black

67.7 (65/96)

 Coloured

19.8 (19/96)

 White

12.5 (12/96)

Bacterial vaginosis (Nugent Score 7–10) [% (n/N)]a

45.3 (43/95)

Bacterial and protozoal infections [% (n/N)]a

T. vaginalis

9.5 (9/95)

C. trachomatis

8.4 (8/95)

M. genitalium

3.2 (3/95)

N. gonorrhoea

2.1 (2/95)

Eligible (BV+/STI-) [% (n/N)]a

34.7 (33/95)

  1. aOne participant tested HIV positive, thus screening was aborted